Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.39 |
| ▸ | EPOR | P19235 | 6/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | SCNN1A | P37088 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.38 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1428409 | 0.94 | KCNH2 (0.54) | KCNH2MAPTPSMB5PSMB8PSMB9 | |
| SCHEMBL1134515 | 0.93 | KCNH2 (0.65) | KCNH2MAPTPSMB5PSMB8PSMB9 | |
| SCHEMBL1134630 | 0.90 | KCNH2 (0.62) | KCNH2MAPTPSMB5PSMB8PSMB9 | |
| SCHEMBL11980209 | 0.86 | KCNH2 (0.62) | KCNH2EPORLTA4HEPHX2SCNN1A | |
| SCHEMBL2075136 | 0.85 | KCNH2 (0.61) | KCNH2EPORLTA4HEPHX2SCNN1A | |
| SCHEMBL1134585 | 0.85 | MAPT (0.56) | KCNH2MAPT | |
| Hydrochloric Acid SCHEMBL1134542 | 0.85 | KCNH2 (0.60) | KCNH2EPORLTA4HEPHX2SCNN1A | |
| SCHEMBL11959314 | 0.84 | KCNH2 (0.64) | KCNH2EPORLTA4HEPHX2SCNN1A | |
| SCHEMBL1134587 | 0.84 | SYK (0.53) | KCNH2MAPT | |
| Iodide SCHEMBL1428394 | 0.84 | KCNH2 (0.63) | KCNH2EPORLTA4HEPHX2SCNN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300010-B1 | PYRAZINE DERIVATIVES AS EPITHELIAL SODIUM CHANNEL BLOCKERS | NOVARTIS AG (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-8236808-B2 | Pyrazine derivatives as ENAC blockers | NOVARTIS AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-20110201625-A1 | Organic Comopunds | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| EP-2300010-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009150137-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201625-A1 | Organic Comopunds | OR10J3, CFTR, CLIC1 | KCNH2 49/4885MAPT 1914/4885PSMB5 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.